VKVanessa J. Kumpf

Vanessa J. Kumpf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vanessa J. Kumpf has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacologic Management of Diarrhea in Patients With Short Bowel Syndrome

    by Vanessa J. Kumpf

    Diarrhea associated with short bowel syndrome (SBS) can have multiple etiologies, including accelerated intestinal transit, gastric acid hypersecretion, intestinal bacterial overgrowth, and malabsorption of fats and bile salts. As a result, patients may need multiple medications to effectively control fecal output. The armamentarium of antidiarrheal drugs includes antimotility agents, antisecretory drugs, antibiotics and probiotics, bile acid–binding resins, and pancreatic enzymes. An antidiarrheal regimen must be individualized for each patient and should be developed using a methodical, stepwise approach. Treatment should be initiated with a single first‐line medication at the low end of its dosing range. Dosage and/or dosing frequency can then be slowly escalated to achieve maximal effect while minimizing adverse events. If diarrhea remains poorly controlled, additional agents can be incorporated sequentially. If modification of the regimen is required, a single medication should be altered or exchanged at a time. After each adjustment of the regimen, sufficient time should be permitted to fully assess response (≥3–5 days) before initiating additional changes. SBS‐associated malabsorption is a major obstacle to optimization of an antidiarrheal regimen because drug absorption is impaired. Patients may benefit from high dosages and/or frequent dosing intervals, liquid preparations, or nonoral routes of drug delivery. Although the diarrhea associated with SBS can be debilitating, effective pharmaceutical management has the potential to substantially improve health outcomes and quality of life for these patients.


  • Home Parenteral Nutrition

    by Vanessa J. Kumpf, Emma M. Tillman

    Parenteral nutrition (PN) is a complex therapy that may result in serious harm if not properly prescribed, prepared, and administered. The patient who is discharged home on PN for the first time poses significant safety challenges and requires coordination of care between several healthcare disciplines within and outside the hospital. Use of an experienced prescriber and multidisciplinary team to oversee the home PN therapy is an important measure to optimize safety. Referrals should be made to home health and home infusion agencies with qualified staff; however, this may at times be difficult to assess. A safe discharge also requires transition of care between inpatient clinicians caring for the patient and designated outpatient follow‐up. Home PN and lab orders upon discharge should be clear and comprehensive. The use of a standardized home PN order format is an important measure to ensure accuracy of the order. Patient and/or caregiver education is another vital component to safely providing PN in the home setting and should ideally be initiated prior to discharge. This should include instructions to the patient regarding self‐monitoring and when to call if problems develop. Specific criteria should be identified for the patients regarding when and who to contact for problems that develop after they are discharged home.


  • Complications After Bariatric Surgery: Survey Evaluating Impact on the Practice of Specialized Nutrition Support

    by Vanessa J. Kumpf, Kelsey Slocum, Jeff Binkley, Gordon Jensen

    Background: The rapid growth of obesity rates has affected the practice of specialized nutrition support in various ways. One area that deserves special consideration is the impact that bariatric surgery, in particular complications resulting from bariatric surgery, has made on nutrition support practice. A descriptive survey was designed to evaluate this impact and to assess the various approaches to nutrition assessment and interventions in the postoperative bariatric surgery patient. Methods: A web‐based survey consisting of 17 questions was administered in April 2006 to American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) members with available e‐mail addresses. Participants were queried about professional background, primary practice setting, and various issues related to their involvement in the care of bariatric surgery patients. Results: There were 467 responses returned out of 3400 surveys delivered (14% response rate). Sixty percent of responders estimated they were consulted to see 1–10 patients requiring specialized nutrition support over the previous year as a result of complications of bariatric surgery. The most common indications for specialized nutrition support in these patients were anastomotic leak/fistula (49%) and chronic nausea/vomiting (27%). When estimating calorie goals, 62% used an adjusted body weight, 15% used ideal body weight, and 14% used actual weight. When estimating protein goals, 56% used an adjusted body weight, 29% used ideal body weight, and 8% used actual weight. Conclusion: These observations provide impetus for guideline development and highlight the priority for further research regarding the best practices to ensure that postoperative bariatric surgery patients receive safe and appropriate nutrition support.


  • Parenteral Nutrition‐Associated Liver Disease in Adult and Pediatric Patients

    by Vanessa J. Kumpf

    There are essentially 3 types of hepatobiliary disorders associated with parenteral nutrition (PN) therapy: steatosis, cholestasis, and gallbladder sludge/stones. Reported prevalence rates of PN‐associated liver disease (PNALD) vary greatly, and there are distinct differences between adult and pediatric patients. Various etiologic factors have been evaluated for significance in contributing to PNALD, including enteral feeding history, septic events, bacterial overgrowth, length of intestinal resection, and prematurity/low birth weight. Etiologic factors specifically related to the PN formulation or nutrient intake have also been evaluated, including excessive calorie intake, dextrose‐to‐lipid ratio, amino acid dose, taurine deficiency, IV fat emulsion (IVFE) dose, carnitine deficiency, choline deficiency, and continuous vs cyclic infusion. Minor increases in serum aminotransferase concentrations are relatively common in patients receiving PN therapy and generally require no intervention. The primary indicator of cholestasis is a serum conjugated bilirubin >2 mg/dL. When a patient receiving PN develops liver complications, it is necessary to rule out all treatable causes and minimize other risk factors. All potential hepatotoxic medications and herbal supplements should be eliminated. Modifications to the PN regimen that may be helpful include reduction of calories, reduction of IVFE dose to <1 g/kg/d, supplementation of taurine in the infant, and use of cyclic infusion. Initiation of even small amounts of enteral nutrition and use of ursodiol may be beneficial in stimulating bile flow. In the long‐term PN patient with severe and progressive liver disease, intestinal or liver transplantation may be the only remaining treatment option.